• ImmuCell posted preliminary unaudited Q3 2026 sales of $8 million, up 46% from a year earlier.
• Domestic sales reached $6.9 million, up 29.2% year over year.
• Nine-month sales totaled $25.6 million, a 27.8% increase from the prior-year period.
• Tri-Shield sales rose 51% year over year; Dual-Force increased 36%; functional feed line grew 37%.
• Early sales reporting will be discontinued; revenue will be reported with full quarterly financial results going forward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121605PRIMZONEFULLFEED9844023) on October 12, 2026, and is solely responsible for the information contained therein.